{"title":"[Direct Oral Anticoagulants in elderly with multimorbidity: what precautions?]","authors":"Beatriz Alameda, Sophia Hannou, Julien Derême, Gerasimos Tsilimidos, Lorenzo Alberio, Patrizia D'amelio, Wanda Bosshard Taroni","doi":"10.53738/REVMED.2024.20.893.1978","DOIUrl":null,"url":null,"abstract":"<p><p>Elderly with multimorbidity are at higher risk of accumulating direct oral anticoagulants (DOAC). The presence of renal insufficiency, an extreme age or weight, a limited functional reserve, and a polypharmacy that may interact with DOAC, lead to an increased risk of bleeding. A medication review and an evaluation of DOAC exposure in this population could help identify this risk and better manage it. This evaluation is conducted in collaboration with coagulation experts through calibrated measurement of anti-Xa (rivarobaxan, apixaban and edoxaban), along with D-dimers measurement as a potential tool to assess thrombo-hemorrhagic risk. In the event of DOAC accumulation, experts could then propose personalized intervention, such as a dose reduction or a switch to another DOAC.</p>","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"20 893","pages":"1978-1982"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue medicale suisse","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53738/REVMED.2024.20.893.1978","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Elderly with multimorbidity are at higher risk of accumulating direct oral anticoagulants (DOAC). The presence of renal insufficiency, an extreme age or weight, a limited functional reserve, and a polypharmacy that may interact with DOAC, lead to an increased risk of bleeding. A medication review and an evaluation of DOAC exposure in this population could help identify this risk and better manage it. This evaluation is conducted in collaboration with coagulation experts through calibrated measurement of anti-Xa (rivarobaxan, apixaban and edoxaban), along with D-dimers measurement as a potential tool to assess thrombo-hemorrhagic risk. In the event of DOAC accumulation, experts could then propose personalized intervention, such as a dose reduction or a switch to another DOAC.
期刊介绍:
Destinée aux professionnels de santé, la plateforme revmed.ch regroupe la version électronique de la Revue Médicale Suisse et les applications de formation et d"aide à la prise de décision eRMS. La eRMS est le fruit d’une large collaboration entre institutions et praticiens de Suisse romande.